Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Apatinib + capecitabine + oxaliplatin is a combination regimen used primarily as neoadjuvant therapy for patients with locally advanced gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and colorectal cancer. Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting tumor angiogenesis. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis in rapidly dividing cells. Oxaliplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in cancer cells. The combination has shown promising efficacy and manageable safety profiles in clinical studies for these indications[1][2].
- Brand names
- AitanXelodaEloxatin
- Other names
- apatinib plus XELOXapatinib + XELOXapatinib combined with capecitabine and oxaliplatin
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on apatinib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + capecitabine + oxaliplatin.